Aberdam D

Bremond-Gignac D

Cursiefen C

Daniels JT

Dickman MM

Ferrari G

Ferrari S

Figueiredo FC

Grupcheva C

Koppen C

Lagali N

LaPointe VLS

Notara M

Parekh M

Ritter T

Romano V

Skottman H

Utheim TP

van Velthoven AJH

\ua9 2023 The AuthorsCongenital aniridia is a panocular disorder that is typically characterized by iris hypoplasia and aniridia-associated keratopathy (AAK). AAK results in the progressive loss of corneal transparency and thereby loss of vision. Currently, there is no approved therapy to delay or prevent its progression, and clinical management is challenging because of phenotypic variability and high risk of complications after interventions; however, new insights into the molecular pathogenesis of AAK may help improve its management. Here, we review the current understanding about the pathogenesis and management of AAK. We highlight the biological mechanisms involved in AAK development with the aim to develop future treatment options, including surgical, pharmacological, cell therapies, and gene therapies

Newcastle University E-Prints

English

Future directions in managing aniridia-associated keratopathy

Future directions in managing aniridia-associated keratopathy

Abstract

Similar works

Full text

Available Versions

Newcastle University E-Prints